-
ImmuPharma PLC Appoints Cenkos Securities as Joint Broker
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug development company, is pleased to announce the appointment of Cenkos Securities plc, as Joint Broker to the Company, with immediate effect. Commenting on the appointment of Cenkos, Dimitri Dimitriou, ImmuPharma’s Chief Executive Officer said: “We are delighted to be working more closely with Cenkos. The Cenkos team brings…
-
PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2011.
-
ImmuPharma PLC Appoints Head of Investor Relations
ImmuPharma PLC (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations.
-
ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA
ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status of its Lupus drug candidate Lupuzor™
-
ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger
ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon Inc (Cephalon), its licensee for Lupuzor™, it has regained rights to Lupuzor™, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd (Teva).
